Evidence map›Paper›PMID 37887947›Full record

ArticleNanomaterials (Basel, Switzerland)2023

pH-Sensitive Nanoparticles for Colonic Delivery Anti-miR-301a in Mouse Models of Inflammatory Bowel Diseases.

Junshan Wang, Min Yao, Jiafeng Zou, Wenxing Ding, Mingyue Sun, Ying Zhuge, Feng Gao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Junshan WangDepartment of Gastroenterology, Chongming Branch of Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 202157, China.
Min YaoShanghai Frontier Science Research Base of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Jiafeng ZouShanghai Frontier Science Research Base of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.ORCID 0000-0001-5703-1797
Wenxing DingShanghai Frontier Science Research Base of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Mingyue SunShanghai Frontier Science Research Base of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Ying ZhugeDepartment of Cardiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.ORCID 0000-0003-2952-4302
Feng GaoShanghai Frontier Science Research Base of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.ORCID 0000-0003-0427-6998
East China University of Science and Technology · CNShanghai Jiao Tong University · CNTongji University · CN

Funding

Development Program of China No.2019YFA0904800 to Y.Z.National Nature Science Foundation of China No.32030065, 31722033, 92049304 to Y.Z.Research Unit of New Techniques for Live-cell Metabolic Imaging Chinese Academy of Medical Sciences, 2019-I2M-5-013 to Y.Z.Science and Technology Commission of Shanghai Chongming Municipality No. CKY2020-05 to J.W.Science and Technology Commission of Shanghai Municipality No.10DZ2220500 to F.G.Shanghai Frontier Science Research Base of Optogenetic Techniques for Cell Metabolism Shanghai Municipal Education Commission, grant 2021 Sci & Tech 03-28 to Y.Z.Shanghai Sailing Program No.21YF1410300 to F.G.the Shanghai Committee of Science and Technology No.11DZ2260600 to F.G.
6 · The paper itself

Abstract

Though the anti-miR-301a (anti-miR) is a promising treatment strategy for inflammatory bowel disease (IBD), the degradability and the poor targeting of the intestine are a familiar issue. This study aimed to develop a multifunctional oral nanoparticle delivery system loaded with anti-miR for improving the targeting ability and the therapeutic efficacy. The HA-CS/ES100/PLGA nanoparticles (HCeP NPs) were prepared using poly (lactic-co-glycolic acid) copolymer (PLGA), enteric material Eudragit

Indexed as

anti-miR-301acolon targetinginflammatory bowel diseaseoral nanoparticle delivery systempH-responsive

Identifiers

PMID37887947
PMCPMC10610125
OpenAlexW4387810333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.